Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open tolerability study of subcutaneous anakinra 100 mg in combination with riluzole in patients with amyotrophic lateral sclerosis (ALS)
2010-019218-26Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in amyotrophic lateral sclerosis (ALS), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Safety and tolerability. Started Dec 2010; status: completed.
02
Drugs
anakinra
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2010-019218-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019218-26.